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806Diabetes Mellitus Modifies the Associations
of Serum Magnesium Concentration
With Arterial Calcification and Stiffness
in Incident Hemodialysis Patients
Wei Chen1,2, Jessica Fitzpatrick3, Jose M. Monroy-Trujillo4, Stephen M. Sozio4,5,
Bernard G. Jaar4,5,6, Michelle M. Estrella7,8, Tong Tong Wu9, Michal L. Melamed1,
Rulan S. Parekh3,4,5 and David A. Bushinsky2
1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA; 2Department of Medicine, University of
Rochester School of Medicine and Dentistry, Rochester, New York, USA; 3Department of Medicine and Pediatrics, University of
Toronto, Toronto, Ontario, Canada; 4Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland,
USA; 5Department of Epidemiology, Bloomberg School of Public Health, Baltimore, Maryland, USA; 6Nephrology Center of
Maryland, Maryland, USA; 7Department of Medicine, University of California, San Francisco, San Francisco, California, USA;
8Kidney Health Research Collaborative, San Francisco VA Medical Center, San Francisco, California, USA; and 9Department of
Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USAIntroduction: Magnesium (Mg) may protect against arterial calcification. We tested the hypotheses that a
higher serum Mg concentration is associated with less arterial calcification and stiffness in patients on
hemodialysis (HD) and that these associations are modified by diabetes mellitus.
Methods: We performed cross-sectional analyses of 367 incident HD patients from the Predictors of
Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) cohort. Measures of arterial
calcification and stiffness included coronary arterial calcification (CAC) and thoracic aortic calcification
(TAC) scores, ankle brachial index (ABI; high ABI: >1.4 or incompressible vessels), pulse wave velocity
(PWV), and pulse pressure.
Results: Mean Mg was 1.8  0.2 mEq/l and 58% had diabetes. Among nondiabetic individuals, per 0.1
mEq/l higher Mg, non-zero CAC score was lower (% difference: 15.4%; 95% confidence interval
[CI]: 28% to 0.55%; P ¼ 0.03), the odds of having TAC score >0 and the odds of having high ABI were
lower (odds ratio [OR]: 0.66; 95% CI 0.47–0.93; P ¼ 0.02, and 0.23; 95% CI: 0.06–0.83, P ¼ 0.03, respectively)
while adjusting for demographics, comorbidities, markers of mineral metabolism, and dialysis clearance.
Among diabetic individuals, per 0.1 mEq/l higher Mg, the odds of having TAC score >0 was higher (OR:
1.57; 95% CI: 1.09–2.26; P ¼ 0.02). Mg was not associated with CAC or high ABI among diabetic individuals.
Mg was not associated with PWV or pulse pressure regardless of diabetes status.
Conclusion: Diabetes modified the associations of serum Mg with arterial calcification and stiffness in
incident HD patients. Higher Mg was associated with less arterial calcification and less peripheral arterial
stiffness among nondiabetic individuals, but Mg was only associated with TAC among diabetic individuals
with higher Mg being associated with higher likelihood of having TAC score >0.
Kidney Int Rep (2019) 4, 806–813; https://doi.org/10.1016/j.ekir.2019.03.003
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A rterial calcification is common in patients withchronic kidney disease (CKD).1 Calcification can
lead to arterial stiffness, systolic hypertension, left
ventricular hypertrophy, and ultimately contribute tospondence: Wei Chen, Albert Einstein College of Medicine,
Morris Park Avenue, Ullmann 615, Bronx, New York 10461,
E-mail: weichen@montefiore.org
ved 22 January 2019; accepted 4 March 2019; published
13 March 2019cardiovascular death.1–3 The extent of arterial calcifica-
tion independently predicts cardiovascular morbidity
and mortality.1,2 In patients with CKD, the disturbances
in the metabolism of divalent ions such as calcium,
phosphate, and magnesium (Mg) play an important role
in the development of arterial calcification.4
Whereas calcium and phosphate retention are
known to promote arterial calcification,5 in the past
decade, several studies have suggested that Mg may
protect against arterial calcification.6–10 In rodents,Kidney International Reports (2019) 4, 806–813
W Chen et al.: Magnesium, Arterial Calcification, and Stiffness CLINICAL RESEARCHdietary Mg supplementation prevented vascular and
cardiac calcification.6–8 In 2 small studies of dialysis
patients, oral Mg supplementation decreased carotid
intima-medial thickness.9,10 Both in vitro and in vivo
studies also showed that Mg attenuated phosphate-
induced arterial calcification.11,12 Although the pre-
cise mechanism by which Mg may protect against
arterial calcification is unknown, Mg inhibits calcium
pyrophosphate dehydrate crystal formation,13 increases
the expression of calcification inhibitors, and regulates
the activity of transient receptor potential cation
channel subfamily M member 7 in vascular smooth
muscle cells.14
In this study, we tested the hypothesis that a higher
serum Mg concentration is associated with less arterial
calcification and stiffness among incident hemodialysis
(HD) patients from the Predictors of Arrhythmic and
Cardiovascular Risk in End Stage Renal Disease (PACE)
study. Because diabetes mellitus is a risk factor for both
hypomagnesemia and arterial calcification,15,16 we also
examined whether diabetes modifies the relationship of
serum Mg with arterial calcification and stiffness.
MATERIALS AND METHODS
Study Population
PACE is a prospective study designed to determine
cardiovascular and dialysis-related risk factors associ-
ated with cardiac dysfunction and incidence of sudden
cardiac death in patients on HD. Incident HD patients
receiving regular outpatient HD thrice weekly for less
than 6 months were recruited from 25 free-standing
outpatient HD units and 2 hospital-based outpatient
units in Baltimore, Maryland, and its surrounding area
from 2008 to 2012. The details of eligibility criteria and
recruitment were described previously.17 The PACE
study was approved by the Johns Hopkins School of
Medicine and MedStar Institutional Review Boards. A
total of 568 participants were consented and enrolled at
baseline. For this study, 367 participants were included
for analyses after excluding those with missing serum
Mg (n ¼ 201). The flow chart of study population is in
Supplementary Figure S1.
Measurement of Serum Magnesium
Total serum Mg concentration was measured in the
blood collected on a non-HD day after approximately 8
hours of fasting at the baseline visit. All participants
received HD on a dialysate Mg concentration of 1.0
mEq/l. For the comparisons of participant characteris-
tics, serum Mg levels were categorized into tertiles of
the entire study population: <1.7 mEq/l (n ¼ 112), 1.7–
1.8 mEq/l (n ¼ 135), and >1.8 mEq/l (n ¼ 120). We
considered using the normal range of Mg levels (1.5–
2.0 mEq/l)18 as the reference group, but this approachKidney International Reports (2019) 4, 806–813results in small groups for comparison (n ¼ 34 for
Mg <1.5 mEq/l and n ¼ 44 for Mg >2.0 mEq/l). For the
main analyses of serum Mg with arterial calcification
and stiffness, serum Mg was examined as a continuous
variable.
Measurement of Arterial Calcification and
Stiffness
Outcome variables were coronary arterial calcification
(CAC) score, thoracic aortic calcification (TAC) score,
ankle brachial index (ABI), pulse wave velocity (PWV),
and pulse pressure. Arterial calcification was measured in
the coronary arteries and thoracic aorta using computed
tomography (Aquilon One; Toshiba, Tokyo, Japan) at the
baseline visit.19 To minimize the effect of cardiac motion,
a single prospective electrocardiographic-triggered
acquisition was taken and images were acquired in
mid-diastole within 1 R to R interval of a single heartbeat.
CAC score was quantified using Agatston score.17 TAC
score was calculated as the sum of calcium scores from
ascending and descending thoracic aorta. Of the 367
participants, 287 participants had computed tomography
examination and available CAC scores. TAC scores were
only available in 200 participants because the computed
tomography image window was too small to include the
whole thoracic aorta in 87 participants. Median time for
computed tomography measurement was 3.6 months
(interquartile range 2.7–5.4) after the initiation of chronic
HD.
Arterial stiffness was defined as high ABI, PWV, or
pulse pressure. ABI is the ratio of ankle to brachial
systolic blood pressure, and the lower of the bilateral
ABI measurements was used for analyses.20 Because
development of arterial stiffness is a relatively slow
process,21 we included ABI measurements that were
obtained either at baseline (n ¼ 280) or year 1 (n ¼ 32).
Participants with ABI #0.9 (n ¼ 51) were excluded
from the analyses because an ABI #0.9 indicates the
presence of peripheral arterial disease.22 High ABI was
defined as an ABI >1.4 or having incompressible ves-
sels, and normal ABI as >0.9 and #1.4.23 PWV mea-
surements were taken supine in the carotid and femoral
arteries using Sphygmocor PVx system (AtCor Medical,
West Ryde, Australia), and measured either at baseline
(n ¼ 278) or year 1 (n ¼ 23). Pulse pressure was defined
as seated systolic minus diastolic blood pressure on a
non-HD day. Blood pressure was taken 3 times and the
readings were averaged. There were 261 participants
available for the analyses of ABI, 301 for PWV, and 364
for pulse pressure.
Measurement of Covariates
Confounders were selected a priori and included self-
reported demographic factors (age, sex, and race),807
Table 1. Demographic and clinical characteristics of participants by diabetes status and serum Mg tertiles
Characteristics
Total
(n [ 367)
Nondiabetic individuals (n [ 156) Diabetic individuals (n [ 211)
Total nondiabetic
individuals
Mg <1.7 mEq/l
(n [ 36)
Mg 1.7--1.8
mEq/l (n [ 61)
Mg >1.8
mEq/l (n [ 59)
Total individuals
with diabetes
Mg <1.7 mEq/l
(n [ 76)
Mg 1.7--1.8
mEq/l (n [ 74)
Mg >1.8 mEq/l
(n [ 61)
Age, yr 55  13 53  15 53  17 53  16 54  14 57  11a 57  12 57  11 56  12
Women, n (%) 145 (40) 65 (42) 12 (33) 25 (41) 28 (47) 80 (38) 32 (42) 26 (35) 22 (36)
Black, n (%) 266 (72) 110 (71) 26 (72) 42 (69) 42 (71) 156 (74) 52 (68) 58 (78) 46 (75)
Body mass index 30  8 27  8 27  7 29  9 26  5 31  8a 32  8 30  8 31  8
History of smoking, n (%) 223 (61) 108 (69) 22 (61) 43 (70) 43 (73) 115 (55)a 40 (53) 37 (50) 38 (62)
Education, <grade 11, n
(%)
130 (36) 61 (39) 14 (39) 30 (50) 17 (29) 69 (33) 22 (29) 27 (36) 20 (33)
Serum calcium, mg/dl 8.6  0.6 8.8  0.7 8.6  0.8 8.7  0.6 8.9  0.7b 8.6  0.6a 8.5  0.5 8.6  0.6 8.6  0.6
Serum phosphate, mg/dl 5.2  1.1 5.2  1.2 4.8  1.1 5.1  1.2 5.5  1.2b 5.1  1.1 5.0  1.0 5.2  1.2 5.3  0.9
Serum magnesium, mEq/l 1.8  0.2 1.8  0.3 1.4  0.2 1.8  0.1 2.0  0.2b 1.8  0.2 1.5  0.1 1.8  0.1 2.0  0.1b
Intact parathyroid
hormone, pg/ml
383
(253–570)
371
(243–580)
319
(196–456)
400
(257–638)
375
(252–580)
391
(266–564)
403
(290–570)
391
(247–590)
390
(245–510)
Fetuin-A, g/l 0.51  0.18 0.52  0.18 0.47  0.18 0.52  0.17 0.56  0.19 0.50  0.17 0.47  0.13 0.51  0.18 0.54  0.19
Serum albumin, g/dl 3.7  0.5 3.7  0.5 3.6  0.6 3.7  0.5 3.8  0.4 3.6  0.4a 3.5  0.4 3.6  0.4 3.6  0.5
Hemoglobin, g/dl 10.8  1.2 10.8  1.3 10.5  1.6 10.6  1.4 11.1  1.1 10.8  1.1 10.6  1.1 10.8  1.2 11.1  1.0b
LDL, mg/dl 82 (61–108) 89 (63–115) 89 (59–106) 94 (66–106) 81 (59–124) 80 (60–106) 72 (54–101) 82 (62–110) 79 (59–103)
Calcium-based phosphate
binder, n (%)
135 (37) 55 (35) 8 (22) 26 (43) 21 (36) 80 (38) 27 (35) 28 (38) 25 (41)
Vitamin D therapy,c n (%) 283 (77) 112 (72) 23 (64) 45 (74) 44 (75) 171 (81)a 63 (83) 56 (76) 52 (85)
RAAS blockage, n (%) 141 (42) 59 (41) 15 (45) 21 (38) 23 (43) 82 (43) 26 (38) 29 (45) 27 (47)
Single-pool Kt/V 1.8  0.3 1.9  0.3 1.9  0.4 1.8  0.3 1.9  0.3 1.8  0.3a 1.7  0.3 1.8  0.3 1.8  0.3
LDL, low-density lipoprotein; RAAS, renin-angiotensin-aldosterone system.
aP < 0.05 compared with nondiabetic individuals.
bP for trend <0.05 across serum Mg tertiles for individuals with and without diabetes.
cVitamin D therapy includes both nutritional vitamin D supplement and activated vitamin D therapy.
Note: If normally distributed, values for continuous variables with normal distribution are provided as mean  SD. Otherwise, they are provided as median (interquartile range).
Categorical variables are presented as absolute number with percentage.
CLINICAL RESEARCH W Chen et al.: Magnesium, Arterial Calcification, and Stiffnesseducation level, smoking history, medical history,
serum markers of mineral metabolism, and parameters
of HD. Comorbidities such as diabetes and hyperten-
sion were adjudicated by a committee of physicians.
Serum calcium, phosphate, intact parathyroid hor-
mone, albumin, and hemoglobin levels were averaged
using 3 months of laboratory values collected before a
dialysis session. Fetuin-A level was measured using an
enzyme-linked immunosorbent assay with a coefficient
of variation of 18% (Epitope Diagnostics, San Diego,
CA) in blood collected on a non-HD day. HD adequacy
was assessed by 3-month average single-pool Kt/V
before the study visit. Medication use was recorded
during the study visit. Vitamin D therapy included
both nutritional vitamin D supplement and activated
vitamin D therapy.
Statistical Analyses
Baseline participant characteristics were examined by
diabetes status and serum Mg tertiles. For continuous
variables, 2-sample t-test or Mann-Whitney U test was
used to examine characteristics by diabetes status, and
analysis of variance or Kruskal-Wallis test was used for
serum Mg tertiles. For categorical variables, c2 tests
were used.
CAC and TAC scores were examined as categorical
variables after being dichotomized at 0 (score >0 vs. ¼0).
808Non-zero CAC and TAC scores24 were examined as
continuous variables after log-transformation to meet the
normality assumption. As sensitivity analyses, we
examined the combination of zero and non-zero CAC and
TAC scores as continuous variables after the log-
transformation of the scores plus 1 (i.e., log[scoreþ1]).
For arterial stiffness, high ABI was compared with normal
ABI. PWV and pulse pressure were examined as
continuous variables. PWV was log-transformed to meet
the normality assumption.
Multiple linear regression models were used to
examine continuous outcome variables. Multiple lo-
gistic regression models were used for binary outcome
variables. Models were adjusted for age, sex, race,
diabetes status, smoking history, body mass index,
serum calcium, phosphate, intact parathyroid hormone,
fetuin-A, albumin, hemoglobin, low-density lipopro-
tein, and single-pool Kt/V. The percentage changes in
non-zero CAC, TAC scores, and PWV were calculated
by transforming the b coefficients (% change ¼ 100 
[eb  1]). Effect modification of the association between
serum Mg and arterial calcification/stiffness by dia-
betes status was evaluated by stratified analyses and
using first-order interaction terms. A 2-sided P
value <0.05 was considered statistically significant for
all analyses. All analyses were conducted using STATA
14.1 (StataCorp, College Station, TX).Kidney International Reports (2019) 4, 806–813
Figure 1. Association between serum magnesium (Mg) and arterial calcification (per 0.1 mEq/l higher serum Mg). CAC, coronary arterial
calcification; TAC, thoracic aortic calcification. aAdjusted for age, sex, race, history of diabetes mellitus, smoking, body mass index, serum
calcium, phosphate, intact parathyroid hormone, fetuin-A, albumin, hemoglobin, low-density lipoprotein, and single-pool Kt/V. In the stratified
models, diabetes status was not included as a covariate. *P < 0.05.
W Chen et al.: Magnesium, Arterial Calcification, and Stiffness CLINICAL RESEARCHRESULTS
Participant Characteristics
Mean age of the participants was 55 years; 40% were
women; 72% were black; 211 (58%) participants had
diabetes and all had hypertension (Table 1). These
baseline characteristics were similar compared with the
PACE participants without Mg levels (Supplementary
Table S1). Compared with nondiabetic individuals,
people with diabetes were older and less likely to have
a history of smoking (Table 1). Diabetic individuals also
had higher body mass index and lower single-pool Kt/
V than nondiabetic individuals.
Overall serum Mg concentration (mean  SD) was
1.8  0.2 mEq/l and ranged from 1.1 to 2.4 mEq/l
(Table 1). Serum Mg was similar between nondiabetic
individuals and people with diabetes. Among nondia-
betic individuals, higher serum Mg was associated with
higher serum calcium and phosphate levels. Among
people with diabetes, higher serum Mg was associated
with higher hemoglobin level.
Association Between Mg and Arterial
Calcification
A total of 182 (63%) participants had CAC score>0 and
100 (50%) had TAC score >0. Among all participants,
serum Mg level was associated only with non-zero CAC
scores (Figure 1). Per 0.1 mEq/l higher Mg, non-zero
CAC score was 14.6% lower (adjusted %
difference: 14.6%; 95% CI: 24.6% to 3.1%; P ¼
0.02). Among nondiabetic individuals, higher serumKidney International Reports (2019) 4, 806–813Mg was associated with lower non-zero CAC score and
lower odds of having a TAC score >0. Per 0.1 mEq/l
higher Mg, non-zero CAC score was 15.4% lower
(adjusted % difference: 15.4%; 95% CI: 28%
to 0.55%; P ¼ 0.03) and the odds of having a TAC
score >0 versus having a score of 0 was 34% lower
(adjusted OR: 0.66; 95% CI: 0.47–0.93; P ¼ 0.02).
Among people with diabetes, serum Mg was only asso-
ciated with TAC score >0 in the adjusted model. The
odds of having a TAC score >0 versus having a score of
0 was 57% greater (adjusted OR: 1.57; 95% CI: 1.09–2.26;
P ¼ 0.02) per 0.1 mEq/l higher Mg. The interaction term
for serum Mg and diabetes status was only significant for
TAC when the TAC score was dichotomized at 0 (P ¼
0.003, Supplementary Table S2). Sensitivity analyses
examining the combination of zero and non-zero CAC and
TAC scores as continuous variables yielded similar results
(Supplementary Figure S2).
Association Between Serum Mg and Arterial
Stiffness
Thirty-nine (15%) participants had a high ABI. Me-
dian PWV was 10.4 (interquartile range 8.0–12.7)
meter per second. Mean pulse pressure was 63  18
mm Hg. Among all participants, serum Mg was only
associated with high ABI in the adjusted model
(Figure 2). Per 0.1 mEq/l higher serum Mg, the odds
of having high versus normal ABI was 19% lower
(adjusted OR: 0.81; 95% CI: 0.67–0.98; P ¼ 0.03).
Similarly, among nondiabetic individuals, serum Mg
was only associated with high ABI in the adjusted809
Figure 2. Association between serum Mg and arterial stiffness (per 0.1 mEq/l higher serum Mg). aAdjusted for age, sex, race, history of
diabetes mellitus, smoking, body mass index, serum calcium, phosphate, intact parathyroid hormone, fetuin-A, albumin, hemoglobin, low-
density lipoprotein, and single-pooled Kt/V. In the stratified models, diabetes status was not included as a covariate. *P < 0.05.
CLINICAL RESEARCH W Chen et al.: Magnesium, Arterial Calcification, and Stiffnessmodel. Per 0.1 mEq/l higher serum Mg, the odds of
having high versus normal ABI was 77% lower
(adjusted OR: 0.23; 95% CI: 0.06–0.83; P ¼ 0.03).
Among people with diabetes, serum Mg was not
associated with any measure of arterial stiffness. None
of the interaction terms for serum Mg and diabetes
status were statistically significant (Supplementary
Table S2).CONCLUSION
In this study, we found that higher serum Mg was
associated with lower arterial calcification and stiffness in
incident HD patients, but only among those without
diabetes. Diabetes mellitus qualitatively modified the as-
sociations of serum Mg concentration with arterial calci-
fication and stiffness, especially the association between
serum Mg and TAC. Among nondiabetic individuals,
higher serum Mg was associated with lower CAC scores,
lower likelihood of having TAC score >0, and lower
likelihood of having high ABI. However, among people
with diabetes, higher serum Mg was associated with
higher likelihood of having TAC score >0 and not
associated with other measures of arterial calcification or
stiffness. Prior studies have demonstrated that a higher
Mg level is associated with less arterial calcification,25–29
but we found no studies that have reported whether
diabetes modifies this relationship.
Why diabetes modifies the association between
serum Mg and aortic calcification is unclear but may be
due to the differences in the pathways that CKD and
diabetes induce arterial calcification. Both CKD and
diabetes are proinflammatory states with elevated cy-
tokines that can induce osteogenic differentiation of810vascular smooth muscle cells30 and can lead to both
medial and intimal calcification.31 Patients with CKD
have disordered mineral metabolism that contributes to
the development of arterial calcification,4,32 whereas
patients with diabetes often develop arterial calcifica-
tion due to poor glycemic control and insulin resis-
tance. Patients with diabetes generally do not have
disordered metabolism of calcium or phosphate before
developing advanced CKD.33 In our study, serum Mg
was not associated with CAC or arterial stiffness among
people with diabetes. The protective effect of Mg on
arterial calcification may be independent of the meta-
bolic abnormalities solely associated with diabetes; or
the factors inducing arterial calcification in diabetes
may mask any effect of Mg on preventing calcification.
Why TAC but not CAC was higher with increasing
serum Mg in people with diabetes is not clear and will
require further study.
Diabetic nephropathy is one of the most common
causes of end stage renal disease.34 If confirmed in
larger studies, the findings of this study may have
important implications on Mg supplementation in
preventing arterial calcification. In animal studies,
dietary supplementation of Mg prevented the
development of arterial and cardiac calcification,6–8
and this effect was independent of the action of Mg
as an intestinal phosphate binder.8 In patients on HD,
observational studies showed an inverse relationship
between serum Mg and arterial calcification.25–29
Two small clinical trials (n ¼ 47 and n ¼ 54)
demonstrated that oral Mg supplementation
decreased carotid intima-media thickness in patients
on HD.9,10 Using a serum marker of calcification
propensity, a recent single-center, randomizedKidney International Reports (2019) 4, 806–813
W Chen et al.: Magnesium, Arterial Calcification, and Stiffness CLINICAL RESEARCHcontrolled trial35 showed that increasing dialysate
Mg from 1.0 to 2.0 mEq/l for 4 weeks increased the
potency of serum Mg to inhibit calcification.36 These
studies have led to the idea of supplementing Mg in
dialysis patients,6–10,37 even before the results of an
on-going clinical trial.38 The results of our study
suggest that the diabetes status of patients should be
considered in clinical trials.
Over the past decades, the commonly used concen-
tration of dialysate Mg decreased from approximately
1.5 mEq/l in the 1970s to 1.0 mEq/l currently.39 This
change was due, in part, to the concern that hyper-
magnesemia could suppress parathyroid hormone and
interfere with the process of bone mineralization,
contributing to adynamic bone disease.40,41 In a Japa-
nese cohort of patients on HD,42 higher serum Mg was
associated with lower intact parathyroid hormone. In
this study, serum Mg was not associated with intact
parathyroid hormone in participants with or without
diabetes. (Table 1). Compared with the Japanese cohort,
serum Mg level in our cohort was lower (mean 1.76 vs.
2.1 mEq/l) and intact parathyroid hormone level was
higher (median 383 vs.126 pg/ml). Future studies are
needed to determine the potential benefits and risks of
Mg supplementation on not only arterial calcification,
but also on parathyroid hormone levels, bone strength,
and bone architecture in patients with CKD.
Our study has limitations. First, because it is a cross-
sectional study, temporal relationship of serum Mg
with arterial calcification and stiffness could not be
studied, thus limiting the inference of a potential causal
relationship. Second, because Mg is mainly intracel-
lular, serum Mg does not accurately reflect total body
Mg; however, serum Mg is the only Mg measurement
available in clinical setting. Third, serum Mg was
collected on different non-HD days during the study
visit. We do not have the day of the week on which
blood was collected with respect to participants’ dial-
ysis schedules. All participants received dialysis thrice
weekly, thus there was a 2-day break between the last
session of the week and the first session of the next one.
Serum Mg drawn in the beginning of the week might
be higher than that done later during the week. Fourth,
the interaction terms for serum Mg and diabetes were
not significant except for the comparison between TAC
>0 and TAC ¼ 0. This could be because we need a
bigger sample to test the interactions. However, we
performed stratified analyses and found that the asso-
ciations of serum Mg with arterial calcification and
stiffness were qualitatively different between partici-
pants with and without diabetes. Last, residual renal
function may influence the association of serum Mg
with arterial calcification and stiffness. Only a third of
participants had available data on residual renalKidney International Reports (2019) 4, 806–813function. Due to the limitation in sample size, we did
not include residual renal function in our analyses.
There are several strengths in our study. We
demonstrated that diabetes modified the relationship of
serum Mg with arterial calcification and stiffness in
incident HD patients. This finding not only provides
insight into the development of arterial calcification in
CKD and diabetes, it also has an important clinical
implication, as Mg supplementation is being considered
as a therapy for arterial calcification in CKD. We
attempted a thorough evaluation of arterial calcification
by quantifying CAC and TAC and by assessing arterial
stiffness using ABI, PWV, and pulse pressure with
standardized protocols.17 Prior studies examined the
relationship between Mg and arterial calcification using
only 1 measure of calcification.26–28,43 As some arteries
are more prone to develop medial calcification than
others,44 it is important to study calcification in
different arterial beds.
In this study, we evaluated the association of serum
Mg concentration with arterial calcification and stiff-
ness by diabetes status in incident HD patients, and
found that diabetes modified these relationships.
Among nondiabetic individuals, higher serum Mg was
associated with less arterial calcification and less pe-
ripheral arterial stiffness; however, among people
with diabetes, Mg was not associated with arterial
calcification or stiffness except that higher serum Mg
was associated with higher likelihood of have a TAC
score >0. If confirmed in larger studies, the findings
may have a significant clinical implication on the use
of Mg supplements in HD patients. Diabetes status of
participants should be considered in designing clinical
trials that examine the effect of Mg on arterial
calcification.
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